ClinicalTrials.gg
RecruitingNCT06372379eCREAM-UC2Updated Oct 9, 2026

Development of a Multipurpose Dashboard to Monitor the Situation of Emergency Departments

An observational study in Emergency Medicine, sponsored by Mario Negri Institute for Pharmacological Research. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Mario Negri Institute for Pharmacological Research · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 9, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
162,000
Ages
18 Years and older
Sex
All
01

Study summary

An emergency department (ED) is a healthcare service that provides the first clinical assessment and treatment to patients with various acute conditions. These departments, however, are often overwhelmed by the large volume of patients. As a consequence, ED crowding has become a global concern and has been correlated to reduced timeliness and effectiveness of care and increased patient mortality. Concerning input, 20% to 30% of patients are brought to the ED by ambulance; the remaining are self-presenting for the vast majority. Notably, non-urgent conditions characterize a high proportion of all ED visits worldwide, and almost all of these visits involve self-presenting patients. Increasing the awareness of these patients about the mandate of EDs and the real-time situation of the neighboring emergency departments has the potential to reduce the self-presentation of patients with minor, non-urgent conditions. Such patient empowerment can be achieved through a dashboard. Concerning throughput, working in the ED requires emergency physicians and nurses to treat many patients at once while maintaining situational awareness of the surroundings. This is especially true for the head of the department, but it also holds for all physicians. It can be crucial, for example, for physicians to know if there is a bottleneck in the flow of the entire patient care process, such as a particularly high average waiting time for radiology reporting or cardiologic consultation. The availability of this information allows countermeasures to be put in place to regain efficiency. All this can be achieved through dedicated dashboards automatically fed from various information system. In addition, appropriate dashboards also enable health policymakers to monitor specific epidemiological phenomena, such as the emergence of certain infectious diseases, in a timely manner.

02

Conditions studied

  • Emergency Medicine
03

In context

Lead sponsor

Mario Negri Institute for Pharmacological Research is the lead sponsor of 161 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

All adult patients who arrived at participating emergency departments between January 1, 2025 and December 31, 2025

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult
  • Arrived at emergency department between 1 January 2025 and 31 December 2025

Exclusion criteria

Exclusion Criteria:

- None

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
162,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adults who attended the emergency department

    Other: no intervention

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Daschboards

    Develop three different control panels for three different end-users, specifically: 1. Dashboard for citizens 2. Dashboard for healthcare providers 3. Dashboard for healthcare policymakers The aim is to extract the needed information from heterogeneous sources and to feed the dashboards according to the needs of the end-users. On the whole, for citizens, the dashboard will be designed to empower them to choose the most appropriate ED to attend or to consider a different, more relevant or more efficient, health service; for healthcare providers, the dashboard will provide a clear and immediate picture of the ED situation in terms of patient flow and workflow; for healthcare policymakers, the dashboard will provide the ability to monitor specific phenomena of interest, such as ED crowding level, possible incidence of pre-specified epidemiological phenomena, availability and timeliness of primary and secondary patient transfers, ambulance offload delays, etc.

    Time frame: September 2024 - September 2027

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The anonymized data derived from this study could be shared for secondary use in the context of research projects.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jan 2027, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
Apr 18, 2024
StartActual
Sep 22, 2025
Primary completionEst.
Jan 2027was Jun 2026
CompletionEst.
Feb 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Jan 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Jun 2026→Jan 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06372379
Collaborators
Astir s.r.l., Orobix Life S.r.l., Fondazione Bruno Kessler
Responsible party
Sponsor
First posted
Apr 18, 2024
Start date
Sep 22, 2025
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Chiara Pandolfini
Contact
chiara.pandolfini@marionegri.it
0039 02 39014 253
Giulia Ghilardi
Contact
giulia_irene.ghilardi@marionegri.it
0039 035 4535 389
Guido Bertolini, MD
principal investigator · Istituto Di Ricerche Farmacologiche Mario Negri

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion